Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This revolutionary drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in research studies. By boosting these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately leads to significant slimming. While further